Robert Knobler, MD of the Medical University of Vienna, Vienna, Austria talks about extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma (the particular varient being Sézary syndrome) at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Extracorporeal photopheresis was invented in 1983 and became well known worldwide in 1987 when the first study was published in the New England Journal of Medicine. Prof. Knobler's role was to review the literature and the progress that has been done in the past 30 years in the use of this therapy. The literature of over 37 published papers (review articles and retrospective studies) have been reviewed and it has been found that the efficacy of this therapy, which was shown to be significant in inducing complete remission (CR) in refactory patients as well as patients who were responding to other therapies but not optimally, has been reproduced in over 1200 patients that were treated with this technology. The complete remission (CR) rates
Hundreds of lymphoma clinical trials are being conducted at hospitals, cancer centers, and doctors' offices around the country. The Lymphoma Research Foundation provides a free Clinical Trials Information Service for patients who wish to learn more about clinical trials. Learn more at www.lymphoma.org/clinicaltrials.
One of the most common forms of T-cell lymphoma is cutaneous T-cell lymphoma (CTCL). The two most common types of CTCL are mycosis fungoides and Sezary syndrome. Learn more about CTCL, treatment options and patient resources at www.lymphoma.org.